TB-500 (Thymosin Beta-4): Uses, Evidence, and Status
TB-500 is a synthetic peptide sold as a research chemical, not an FDA-approved drug or supplement. It is derived from thymosin beta-4 (Tβ4), a naturally occurring protein with real biological functions, but TB-500 is not the same molecule as Tβ4, and that distinction matters more than most vendor descriptions acknowledge. If you are seeing it discussed in recovery and injury forums, here is what the current evidence actually shows.
What Is TB-500, and Why Does It Matter That It Is Not Thymosin Beta-4?
Thymosin beta-4 is a 43-amino-acid peptide found in virtually every human and animal cell, concentrated particularly in the thymus and in platelets. Its established biological roles include sequestering actin (a structural protein central to cell movement), promoting cell motility, accelerating wound healing, stimulating angiogenesis (the formation of new blood vessels), and modulating immune responses.
TB-500 is something different: a synthetic 7-amino-acid fragment with the sequence LKKTETQ, taken from the actin-binding region of Tβ4. The premise behind it is that this short segment may be the "minimal active motif" responsible for some of Tβ4's tissue-repair effects. But TB-500 does not contain the Ac-SDKP motif, which occupies the first four amino acids of the full protein and is believed to mediate cytoprotective effects during acute ischemia (tissue injury from restricted blood flow). Effects attributed to full Tβ4, including some of the cardiovascular research, cannot be transferred directly to TB-500 (Innerbody TB-500 Guide 2026; Pure Health Peptides TB-500 vs Tβ4).
This is not a minor technicality. A fragment may behave differently from its parent molecule in terms of potency, receptor binding, half-life, and side-effect profile. Treating the two as equivalent is a common error in community discussions.
What Mechanism Is TB-500 Proposed to Work Through?
The proposed mechanism centers on the same actin-sequestration pathway as full Tβ4. By binding free actin monomers within cells, the peptide is thought to promote cellular motility, which is a necessary step in tissue repair: cells must be able to migrate into damaged areas to rebuild structure.
Downstream of that, animal-model studies using the full Tβ4 protein have shown faster wound closure, reduced markers of inflammation, and some degree of cardiac tissue protection after injury. Angiogenesis, the sprouting of new capillaries into healing tissue, has also been observed in preclinical work. These findings are real. The problem is that most of the mechanistic and outcome data in the literature comes from studies using full Tβ4, not the TB-500 fragment, and it comes from rodent and equine models rather than humans (Dr. Oracle TB-500 article).
What Does the Human Evidence Actually Show?
Nothing. TB-500, as a specific compound, has no published human clinical trials as of mid-2026. Zero. There is no dose-finding study, no safety pharmacology study, no controlled trial of any outcome in any human population.
Full thymosin beta-4 has attracted some human cardiovascular research (studies exploring its role in cardiac repair after infarction), but that work concerns the intact 43-amino-acid protein and an entirely different indication, not the actin-binding fragment used in the injury-recovery context. Extrapolating cardiac Tβ4 data to TB-500 as a musculoskeletal recovery tool is a double leap: different molecule, different indication (Dr. Oracle TB-500 article, 2025).
Animal evidence for wound healing and soft-tissue repair is substantial across multiple species. But species-specific differences with peptides are common, dose-response relationships do not translate reliably across species, and the lack of human pharmacokinetic data means nobody knows how long TB-500 stays active in the human body or what it does there.
For peptides for joints and tendons more broadly, this evidence gap is a consistent theme: strong mechanistic rationale, compelling animal data, and a wall of silence where human trials should be.
What Do People Actually Use TB-500 For?
The off-label community use cases reported most frequently are soft-tissue and muscle injury recovery, tendon and ligament healing, and general tissue repair after training stress or surgery. TB-500 is also commonly paired with BPC-157, another research peptide with a different proposed mechanism, on the theory that the two may act on complementary pathways.
None of these use cases are FDA-approved indications. They are extrapolations from animal data and from physiological reasoning about what the actin-binding domain theoretically does. People use it this way because it is accessible as a research chemical, not because clinical trials have validated these applications in humans.
TB-500 vs BPC-157: How Do They Compare?
These two peptides are frequently discussed together and often stacked. Here is how they differ on the factors that matter for someone evaluating either:
| Factor | TB-500 | BPC-157 |
|---|---|---|
| Proposed mechanism | Actin sequestration, cell motility, angiogenesis via actin-binding domain of thymosin beta-4 | Nitric oxide pathway modulation, growth hormone receptor interaction, angiogenesis via body protection compound sequence |
| Evidence base | Animal models (wound healing, cardiac protection in full Tβ4); zero published human trials for TB-500 specifically | Animal models (gut healing, tendon repair, neurological); very limited human clinical data; one small human study in ulcerative colitis patients |
| Typical reported use case | Soft-tissue injury, muscle tear recovery, tendon/ligament healing | Gut healing, systemic injury recovery, neurological support, tendon repair |
| WADA status | Explicitly prohibited (S2, all times) | Prohibited (S2, all times) |
| FDA status | Not approved; under PCAC review | Not approved; under PCAC review |
Stacking two compounds with no human trial data is not additive evidence. It is two open questions running simultaneously, which makes attributing any outcome, positive or negative, to either compound very difficult. The BPC-157 and TB-500 stack is widely discussed in communities for that exact reason: combined use is common even though the combined unknowns are compounded.
What Is TB-500's Regulatory and Legal Status?
TB-500 is not FDA-approved for any indication. It is not a licensed drug, not a dietary supplement, and not cleared for human therapeutic use in the United States.
On April 22, 2026, the FDA removed TB-500 from its Category 2 interim 503A compounding bulks list, alongside BPC-157. Both are scheduled for Pharmacy Compounding Advisory Committee (PCAC) review on July 23-24, 2026. Being scheduled for review does not mean the FDA has cleared them; it means the committee has not yet issued a formal determination. They are not approved for compounding. Check FDA.gov directly for any status update following that July meeting, because the situation may change (FDA PCAC July 2026 advisory committee calendar).
Under WADA's 2026 Prohibited List, TB-500 is explicitly named under S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics) and is prohibited at all times, meaning both in-competition and out-of-competition use is banned for athletes subject to anti-doping rules (WADA Prohibited List 2026). If you compete under any organization that adopts the WADA code, this is not a gray area.
The broader legal question for non-athletes is addressed in more detail in are peptides legal in 2026, but the short version is that TB-500 sold as a "research chemical" occupies genuinely ambiguous territory, and that ambiguity is not the same as legality.
What Safety Considerations Apply?
No established safe dose exists for TB-500 in humans. No safety pharmacology data has been published. What that means practically:
Immunogenicity is unknown. When synthetic peptides are introduced into the human body, the immune system can potentially mount a response against them, including against the endogenous proteins they resemble. Whether TB-500 triggers this in humans has not been studied.
Contamination risk is real. TB-500 is sold via unregulated vendors with variable quality control. A certificate of analysis (COA) showing high HPLC purity is necessary but not sufficient: it does not tell you the product is sterile or free of bacterial endotoxins. Legitimate quality testing requires LAL endotoxin testing in addition to purity analysis. A contaminated injectable product can cause serious localized or systemic reactions regardless of what the peptide itself would do.
Long-term effects are unknown. No chronic toxicity data exists for TB-500 in humans. Animal studies typically run over defined, relatively short timeframes. What repeated administration over months or years does in humans is not known.
Competitive athletes face an additional concrete risk: a positive anti-doping test. Unlike some banned substances where the detection window is short, peptide testing methodologies are improving. This is worth factoring in independently of any health consideration.
What to Discuss With a Provider
If you are considering TB-500 under medical supervision, there are several questions worth raising explicitly:
First, ask whether the product being discussed is actually the 7-amino-acid LKKTETQ fragment or a different formulation. Product labeling in the research chemical space is inconsistent, and what is sold as "TB-500" varies. Composition and quality vary between vendors.
Second, ask specifically how a dosing decision would be made in the absence of human clinical trial data. Any credible provider should be able to explain the reasoning process: whether they are extrapolating from animal data, from full Tβ4 research, or from clinical experience with similar peptides, and what that means for confidence in the dose.
Third, discuss peptide cycling practices and whether a structured on/off approach is warranted. In the absence of human data, minimizing cumulative exposure is a reasonable harm-reduction principle.
How Myo Fits Into This Picture
One underappreciated problem with any research-chemical peptide protocol is that outcomes are almost entirely subjective and untracked. Someone reports "my knee feels better after six weeks," but they have no baseline, no daily check-ins, no record of confounding variables like sleep, training load, or concurrent interventions. That makes it impossible to know whether the peptide did anything.
Myo, an iOS tracking and education app from PixelPort LLC, is built for exactly this gap. If you are working with a provider on a TB-500 protocol, logging daily subjective recovery scores, injection dates, training load, sleep quality, and notable symptoms inside Myo gives you something more useful than memory: a structured timeline of how you actually felt across the cycle. That does not validate the peptide, and Myo is not a medical tool. But "I tracked it and here is what the data shows" is a meaningfully better conversation to have with your provider at follow-up than "I think it helped." The same principle applies if you are tracking GLP-1 side effects or any other intervention where subjective response matters.
What Should You Take Away?
TB-500 is a real compound with plausible mechanistic rationale drawn from legitimate Tβ4 biology. The animal data on tissue repair is genuine. The jump from "this works in rodents via a plausible mechanism" to "this is safe and effective for humans" is the problem, and right now that gap is not bridged by any clinical evidence.
It is not FDA-approved. It has no published human trials. It is explicitly banned by WADA. Its regulatory status is under active review with a determination expected from the PCAC in July 2026. These are not bureaucratic footnotes. They are the relevant facts for anyone making a decision about whether to use it.
If your goal is injury recovery and you are working with a medical provider who has reviewed your situation, that conversation is the right place to have this discussion, with all of the above on the table.
References
- Innerbody TB-500 Guide 2026. "Thymosin Beta-4 and TB-500." https://www.innerbody.com/thymosin-beta-4-and-tb-500
- Pure Health Peptides. "TB-500 vs Thymosin Beta-4: Understanding the Key Differences." https://purehealthpeptides.com/tb-500-vs-thymosin-beta-4-understanding-the-key-differences/
- Dr. Oracle. "What Are BPC-157 and TB-500?" https://www.droracle.ai/articles/594436/what-are-bpc-157-body-protection-compound-157-and-tb-500
- WADA. "2026 Prohibited List." https://www.wada-ama.org/en/prohibited-list
- FDA Advisory Committee Calendar. "July 23-24, 2026 Meeting of the Pharmacy Compounding Advisory Committee." https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
Frequently asked questions
What is TB-500 and how is it different from thymosin beta-4?
Thymosin beta-4 (Tβ4) is a naturally occurring 43-amino-acid protein found in virtually all human and animal cells, with well-established roles in wound healing, cell motility, and immune modulation. TB-500 is a synthetic 7-amino-acid fragment (sequence LKKTETQ) derived from the actin-binding domain of that protein. The two are not interchangeable: TB-500 lacks the Ac-SDKP motif present in full Tβ4, so effects attributed to the full protein may not apply to the fragment. Research on each should be evaluated separately (Innerbody TB-500 Guide 2026; Pure Health Peptides TB-500 vs Tβ4).
Does TB-500 actually speed recovery?
Animal studies suggest the actin-binding domain of thymosin beta-4 may promote tissue repair, reduce inflammation, and support angiogenesis (new blood vessel formation). However, TB-500 as a specific compound has zero published human clinical trials, so whether those preclinical findings translate to humans is genuinely unknown. Community reports of faster recovery exist, but they are anecdotal and uncontrolled. Any claim of established human efficacy for TB-500 goes beyond what the current evidence supports (Dr. Oracle TB-500 article, 2025).
Is TB-500 legal or FDA-approved?
TB-500 is not FDA-approved for any indication in humans. As of April 22, 2026, it was removed from the FDA's Category 2 interim compounding bulks list alongside BPC-157 and is scheduled for Pharmacy Compounding Advisory Committee (PCAC) review on July 23-24, 2026. It is not cleared for compounding, and its regulatory status may change after that review. Check FDA.gov for the current status before drawing conclusions (FDA PCAC July 2026 advisory committee calendar).
Is TB-500 banned in sports?
Yes. TB-500 appears explicitly on the WADA 2026 Prohibited List under category S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics), prohibited at all times, both in and out of competition. Athletes subject to anti-doping rules who use TB-500 face sanctions regardless of intent or therapeutic rationale. If you compete under any organization that adopts the WADA code, this is a hard stop (WADA Prohibited List 2026).
How is TB-500 typically administered?
In the research and community context, TB-500 is typically reconstituted from a lyophilized (freeze-dried) powder and administered via subcutaneous or intramuscular injection. No validated human dose, schedule, or route has been established through clinical trials. Any figures circulating online are community conventions extrapolated from animal research, not clinical recommendations. Administration decisions belong with a licensed medical provider who can assess your individual situation.
Keep reading
BPC-157: What It Is, the Evidence, and the Legal Reality (2026)
BPC-157 explained: what the body protection compound is, what the mostly animal evidence shows, its non-FDA-approved status, and why a provider matters.
The BPC-157 + TB-500 Stack: What People Run and Why
The BPC-157 plus TB-500 stack explained: the theory behind pairing them, the evidence gap, the regulatory reality, and why two unproven peptides add risk.
Peptides for Joints and Tendons: What the Research Actually Shows
Peptides for joints and tendons: what BPC-157, TB-500, and collagen peptides claim vs what research supports, the evidence gaps, and why a provider should lead.